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RESEARCH ARTICLE Open Access
HER2 regulates HIF-2α and drives an
increased hypoxic response in breast
cancer
Edward J. Jarman1,3* , Carol Ward1, Arran K. Turnbull1, Carlos Martinez-Perez1, James Meehan1,
Chrysi Xintaropoulou1, Andrew H. Sims2 and Simon P. Langdon1
Abstract
Background: Tumour hypoxia is a driver of breast cancer progression associated with worse prognosis and more
aggressive disease. The cellular response to hypoxia is mediated by the hypoxia-inducible transcription factors HIF-1
and HIF-2, whose transcriptional activity is canonically regulated through their oxygen-labile HIF-α subunits. These
are constitutively degraded in the presence of oxygen; however, HIF-1α can be stabilised, even at high oxygen
concentrations, through the activation of HER receptor signalling. Despite this, there is still limited understanding
on how HER receptor signalling interacts with HIF activity to contribute to breast cancer progression in the context
of tumour hypoxia.
Methods: 2D and 3D cell line models were used alongside microarray gene expression analysis and meta-analysis
of publicly available gene expression datasets to assess the impact of HER2 overexpression on HIF-1α/HIF-2α
regulation and to compare the global transcriptomic response to acute and chronic hypoxia in an isogenic
cell line model of HER2 overexpression.
Results: HER2 overexpression in MCF7 cells leads to an increase in HIF-2α but not HIF-1α expression in
normoxia and an increased upregulation of HIF-2α in hypoxia. Global gene expression analysis showed that
HER2 overexpression in these cells promotes an exaggerated transcriptional response to both short-term and
long-term hypoxia, with increased expression of numerous hypoxia response genes. HIF-2α expression is
frequently higher in HER2-overexpressing tumours and is associated with worse disease-specific survival in
HER2-positive breast cancer patients. HER2-overexpressing cell lines demonstrate an increased sensitivity to
targeted HIF-2α inhibition through either siRNA or the use of a small molecule inhibitor of HIF-2α translation.
Conclusions: This study suggests an important interplay between HER2 expression and HIF-2α in breast
cancer and highlights the potential for HER2 to drive the expression of numerous hypoxia response genes in
normoxia and hypoxia. Overall, these findings show the importance of understanding the regulation of HIF
activity in a variety of breast cancer subtypes and points to the potential of targeting HIF-2α as a therapy for
HER2-positive breast cancer.
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Background
The rapid growth of solid tumours often results in the
development of hypoxic regions. This occurs as inces-
sant growth and vascular abnormalities lead to insuffi-
cient perfusion of the tumour mass [1, 2]. Areas of
hypoxia can be found in as many as half of all breast
cancers [3] and are directly linked to aggressive disease
and poor response to chemo- and radiotherapy [4].
The cellular response to hypoxia is primarily mediated
by the hypoxia-inducible factor (HIF) family of tran-
scription factors. HIFs form heterodimeric transcription
factors consisting of an oxygen-labile α-subunit (HIF-α)
and an oxygen-independent HIF-β subunit (predomin-
antly HIF-1β). The downstream effects of HIF activity
are determined by which α subunit is involved; HIF-1α
and HIF-2α have been shown to be the main drivers of
the cellular response to low oxygen, whilst HIF-3α is
considered a dominant negative regulator of HIF activity.
Canonical regulation of hypoxia-inducible factors occurs
through the oxygen-dependent proteasomal degradation
of HIF-α subunits following ubiquitination by the Von
Hippel-Lindau (VHL) E3 ubiquitin ligase [5]. Recogni-
tion by the VHL complex involves hydroxylation of
HIF-α by the PHD family of prolyl hydroxylases, which
requires molecular oxygen as a substrate [6]. In hypoxic
cells, PHD-mediated hydroxylation of HIF-α is restricted
by the low availability of molecular oxygen. This results
in an accumulation of HIF-α subunits, which are then
able to form active dimers with HIF-β and drive the
transcription of hypoxia response genes [7–9].
HIF-1 activity has been associated with worse progno-
sis in breast cancer [10–12] and is known to drive the
upregulation of genes involved in glycolysis, angiogen-
esis, invasion and a number of other pathologically rele-
vant characteristics [13–16]. Whilst HIF signalling has
historically been largely synonymous with HIF-1, there
has been a growing appreciation of the differences be-
tween HIF-1 and HIF-2 with regard to the genes they
regulate and the downstream responses mediated by
their activation. More recently, analyses of HIF-1 and
HIF-2 targets in breast cancer cell lines have proposed
overlapping but non-redundant functions for HIF-1 and
HIF-2 in breast cancer cells [17–19]. However, previous
research has focussed solely on hormone-driven breast
cancer cell lines and little is known about the roles of
HIF-1 and HIF-2 in the context of growth factor-driven
breast cancers, such as those belonging to the
HER2-positive subtype.
Investigations into HIF-1α expression in breast cancers
have shown correlation with the expression of HER2
[20, 21], a growth factor receptor overexpressed in 20%
of breast cancers [22] and associated with more aggres-
sive disease [23]. Additionally, growth factor signalling
via the HER3 ligand neuregulin-1β has been shown to
drive HIF-1α levels in normoxia through increases in
protein translation and stability in breast cancer cell
lines [24, 25]. This suggests that a non-canonical regula-
tion of HIF-α subunits through growth factor signalling
might promote HIF-mediated pathology in a growth
factor-dependent, oxygen-independent manner. It is un-
clear whether growth factor-driven HIF-α regulation can
broadly affect the cellular response to hypoxia, poten-
tially acting to exacerbate tumour pathology further in
hypoxic regions. Additionally, the contribution of
HIF-2α to growth factor-driven HIF activity in breast
cancer is not known.
In this study, we investigated the role of HER2 overex-
pression and growth factor-driven HIF-2α in normoxic
and hypoxic breast cancer pathology. We demonstrate
that HER2 overexpression enhances the cellular re-
sponse to hypoxia, including the upregulation of genes
implicated in driving breast cancer progression, and es-
tablish that growth factor signalling through HER2 is
able to drive an oxygen-independent upregulation of
HIF-2α through mechanisms different to those previ-
ously shown for HIF-1α. Finally, through HIF-2α-specific
inhibition studies and survival analysis in publicly avail-
able datasets, we provide evidence that HIF-2α may rep-
resent a targetable pathway in HER2-positive breast
cancer.
Methods
Cell lines and culture
Breast cancer cell lines were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with
10% foetal bovine serum, 100 U/ml penicillin and
100 μg/ml streptomycin. Hypoxic cells were grown at
0.5% O2 in a Don Whitley H35 Hypoxystation. The gen-
etically modified MCF7-HER2 cell line was developed in
Kent Osborne’s lab and grown in media supplemented
with 1 mg/ml G418 [26]. The MCF7 cell line was pur-
chased from the ATCC, and both cell lines were tested
and authenticated using STR profiling by Public Health
England, Porton Down, Salisbury, UK (November 2014).
Protein isolation
Whole cell lysates were obtained by washing cells with
PBS before cellular lysis using a solution of 50 mM Tris
(pH 7.5), 5 mM EGTA (pH 8.5) and 150mM NaCl con-
taining one complete protease inhibitor tablet (Roche),
100 μl phosphatase inhibitor cocktail 2, 100 μl phosphat-
ase inhibitor cocktail 3, 50 μl aprotinin and 100 μl Triton
X-100 per 10ml of solution. After lysis, samples were
centrifuged at 13,000g. Supernatants were collected and
stored at − 70 °C. Each step of this procedure was per-
formed at 4 °C.
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Gel electrophoresis and western blot analysis
Isolated proteins were separated through SDS-PAGE
using a 7.5% bis-acrylamide gel. Separated proteins were
transferred onto an Immobilon-P transfer PVDF mem-
brane. The membrane was blocked and incubated over-
night at 4 °C with primary antibodies (anti-HIF-1α
mouse monoclonal [BD Transduction Laboratories,
610958, 1:250], anti-HIF-2α rabbit polyclonal [Novus Bi-
ologicals, NB100-122, 1:1000], anti-CAIX mouse mono-
clonal [Bioscience Slovakia, M75, 1:1000], anti-HER2
mouse monoclonal [Cell Signalling Technology, #2248,
1:1000], anti-pHER2 (Tyr1221/1222) rabbit monoclonal
[Cell Signalling Technology, #2243, 1:1000], anti-AKT
mouse monoclonal [Cell Signalling Technology, #2920,
1:1000], anti-pAKT (Ser472) rabbit polyclonal [Cell Sig-
nalling Technology. #9271, 1:1000], anti-ERK1/2 rabbit
polyclonal [Cell Signalling Technology, #9102, 1:1000],
anti-pERK1/2 mouse monoclonal (Thr202/Tyr204) [Cell
Signalling Technology, #9106, 1:1000] and anti-α-tubulin
mouse monoclonal [Abcam, Ab7291, 1:10,000]). Anti-
bodies were detected using IRDye 800CW [Li-Cor,
926-32210, 1:10,000] and IRDye 680LT [Li-cor,
926-68021, 1:10,000] secondary antibodies with the
Li-Cor Odyssey imaging system.
Sulforhodamine B assay
Cells were seeded into 96-well plates and incubated for
24 h. Treatment was carried out for 5 days before plates
were fixed by the addition of 50 μl 25% trichloroacetic
acid solution per well for 1 h at 4 °C. Plates were washed
with H2O and air dried before the addition of 50 μl 0.4%
sulforhodamine B solution in 1% acetic acid for 30 min.
Plates were washed in 1% acetic acid and air dried before
the addition of 150 μl 10 mM Tris solution (pH 10.5).
After 30 min absorbance of each well was measured at
540 nm on a BP900 biohit plate reader. HIF-2α inhibitor
C76 was purchased from Merk Millipore (catalogue
number 400087).
3D culture
Cell lines were grown as normal in 2D until 80% conflu-
ent. These were then trypsinised to form a single-cell
suspension, transferred to magnetic spinner flasks
(VWR) and incubated at 37 °C, 5% CO2. Spheroids were
grown for 1–2 weeks with regular media changes until
spheroids of 1–2 mm had formed. These were fixed in
formalin and paraffin embedded.
Immunohistochemistry
Paraffin-embedded spheroids were sectioned and
mounted onto glass slides. Antigen retrieval was per-
formed using a solution of 0.1M citric acid and 0.1M so-
dium citrate. Endogenous peroxidase activity was
quenched using H2O2 solution. Slides were treated with
total protein block (Dako) to inhibit non-specific binding
and were then incubated with primary antibodies for 1 h
at room temperature (anti-HIF-1α mouse monoclonal
[BD Transduction Laboratories, 610958, 1:100], anti-HIF-
2α rabbit polyclonal [Novus Biologicals, NB100-122,
1:200], anti-CAIX mouse monoclonal [Bioscience
Slovakia, M75, 1:1000], anti-LDHA [Cell Signalling Tech-
nology, #3582, 1:400], anti-VEGF mouse monoclonal
[Novus Biologicals, NB100-664, 1:50], anti-CD44 [Cell
Signalling Technology, #3570, 1:50]). Slides were incu-
bated for 30min with Dako envision labelled polymer, be-
fore staining with Dako DAB and substrate buffer. Slides
were counterstained with haemotoxylin and imaged using
the Nanozoomer XR slide scanning system (Hamamatsu).
siRNA treatment
Cells were seeded in 6-well plates (2.5 × 105 per well) or
in 96-well plates (1 × 103 cells per well) with
antibiotic-free medium for 24 h. Cells were transfected
using Dharmafect transfection reagent 1 (Dharamacon)
with the desired concentration of siRNA (HIF-2α siRNA
[J-004814-09, 25 nM], HIF-2α pool siRNA [L-004814-00,
10 nM], non-targeting control siRNA [D-001810-10, 25
nM]). Cells were left for a further 24 h before being
changed into fresh antibiotic-containing media and
grown as per the experiment in normoxic (20% O2) or
hypoxic culture conditions.
Gene expression analysis
RNA was extracted from cells grown in normoxia or hyp-
oxia (0.5% oxygen) for various time points using the
RNeasy Mini Kit (Qiagen). Real-time PCR was performed
using the StepOnePlus Real-Time PCR system (Applied
Biosystems). Reverse transcription and amplification reac-
tions were performed using the Taqman RNA-to-CT
1-Step Kit and Taqman primer sets targeting HIF-1α
(Hs_00153153_m1), HIF-2α (Hs_01026149_m1) and
housekeeping genes PUM1 (Hs_00472881_m1), TBP
(Hs_00427620_m1) and RPL37a (Hs_01102345_m1).
Gene expression values were normalised to the geometric
mean of housekeeping genes.
For transcriptome analysis, RNA was extracted from
cells grown in normoxia, 0.5% oxygen for 24 h (acute
hypoxia), or continually cultured in 0.5% oxygen for >
10 weeks (chronic hypoxia). This was done in biological
triplicate using the RNeasy Mini Kit (Qiagen). RNA was
quantified using the Nanodrop 2000c system (Thermo
Scientific). RNA was reverse transcribed, amplified and
labelled using the Illumina TotalPrep RNA amplification
kit (Ambion). Labelled RNA was hybridised to Human
HT12v4 whole-genome Illumina BeadChip Arrays. Ar-
rays were scanned using the Illumina iScan system. Raw
gene expression files were filtered using the Illumina
probe detection P-value, log2 transformed and quantile
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normalised using the lumi Bioconductor package [27].
Pairwise rank products testing (FDR < 0.05) was used to
identify genes differentially expressed between cell lines
or treatment groups [28]. Enrichment for gene ontology
(GO) terms was tested using the online bioinformatics
platform DAVID 6.7 (Database for Annotation,
Visualization and Integrated Discovery) [29, 30]. Heat-
maps of Log2 gene expression values were created in
TM4 microarray software suite’s MultiExperiment
Viewer [31, 32] and hierarchical clustering by Pearson
correlation with complete linkage was used to compare
samples. Gene expression data was uploaded to NCBI
GEO under the accession GSE111246.
Datasets
To examine gene expression across primary breast can-
cers, an integrated dataset of 2999 samples was interro-
gated. This included 17 gene expression datasets
downloaded from NCBI GEO, summarised, and normal-
ised before integration using ComBat to remove
dataset-specific bias as previously described [33]
(GSE12276, GSE21653, GSE3744, GSE5460, GSE2109.
GSE1561, GSE17907, GSE2990, GSE7390, GSE11121,
GSE16716, GSE2034, GSE1456, GSE6532, GSE3494,
GSE68892). Similarly, three breast cancer cell line panel
gene expression datasets containing 173 samples repre-
senting 77 different cell lines were downloaded from
NCBI GEO (GSE10890, GSE12777, GSE69017) sum-
marised, normalised and batch-corrected [33].
The METABRIC (Molecular Taxonomy of Breast can-
cer International Consortium) dataset is publically avail-
able and was downloaded from cbioportal.org. This
dataset consists of over 2000 fresh-frozen breast cancer
samples with gene expression and associated clinical
data [34]. Survival analysis and Cox proportional hazards
analysis were performed using R. Exhaustive Cox pro-
portional hazards analysis across all cut points was per-
formed using the survivALL package in R [35].
Results
HER2 drives HIF-2α expression in breast cancer
We performed an initial assessment of HIF-2α gene
expression in a combined meta-analysis of 2999 pri-
mary breast tumours stratified by molecular subtype
(details of this dataset have previously been described
[33]). This demonstrated significantly higher expres-
sion of HIF-2α in the HER2-overexpressing samples
when compared to Luminal A, Luminal B and Basal
subtypes, (P < 0.0001, ANOVA with Tukey’s post-test)
with no significant differences between the other sub-
types (Fig. 1a), suggesting a possible role for HER2 in
regulating HIF-2α expression in breast cancer. This
differs to HIF-1α gene expression which is more
highly expressed in more aggressive molecular
subtypes, with Luminal A showing significantly lower
expression than Luminal B, and both HER2-positive
and Basal subtypes showing significantly higher ex-
pression than the Luminal groups (Additional file 1:
Figure S1). The differences in HIF-1α and HIF-2α
gene expression across molecular subtypes suggests
that these factors are regulated in ways which allow
subtype-specific differences in their expression, and in
the case of HIF-2α this appears to be specific to the
HER2-positive subtype. HIF-2α gene expression is also
associated with HER2 in a dataset of 173 breast can-
cer cell lines samples (Additional file 2: Figure S2).
HIF-2α gene expression was significantly higher in
HER2-high cell lines (n = 52) when compared to
HER2-low cell lines (n = 121) groups (P = 0.03). To
investigate this further, we assessed the levels of
HIF-1α and HIF-2α proteins both basally and in re-
sponse to HER receptor activation using the HER3
ligand neuregulin-1β (NRG-1β). This was done in the
MCF7 breast cancer cell line and MCF7-HER2, an
isogenic cell line stably overexpressing the HER2 re-
ceptor [26] (Fig. 1b). Both cell lines exhibited low
levels of HIF-1α in normoxic conditions (20% O2) but
saw HIF-1α induction in normoxia after treatment
with 200 ng/ml NRG-1β (Additional file 3: Figure
S3A/B). This supports the earlier literature which has
shown the NRG-1β-driven increase of HIF-1α in nor-
moxia through protein stabilisation and increased
translation [24, 25]. In contrast, HIF-2α protein levels
did not increase after treatment with NRG-1β in ei-
ther cell line, but was constitutively higher in
MCF7-HER2 when compared to wild type MCF7 cells
(Fig. 1b), suggesting that high HER2 expression may
be associated with higher levels of HIF-2α.
To establish whether HER2 signalling was a direct
driver of HIF-2α in MCF7-HER2 cells we inhibited
HER signalling using lapatinib, a dual tyrosine kinase
inhibitor known to inhibit the activity of both EGFR
and HER2 receptors. Treatment with 10 μM lapatinib
significantly reduced the normoxic expression of
HIF-2α in these cells after 8, 24 and 48 h treatment
(Fig. 1c), demonstrating that HER receptor signalling
is required for the elevated HIF-2α protein levels seen
in these cells. Next, we compared HIF-1α and HIF-2α
transcript levels in MCF7 and MCF7-HER2 cells in
normoxia, as well as in cells grown in hypoxia (0.5%
oxygen) for 8, 24, 48 and 72 h through quantitative
RT-PCR (Fig. 1d). Whilst levels of HIF-1α RNA were
similar, we saw a marked increase in the expression
of HIF-2α in MCF7-HER2 cells when compared to
wild-type MCF7 (Fig. 1d), showing that
HER2-mediated changes in HIF-2α are, at least in
part, invoked at the transcriptional level. In response
to hypoxia, transcriptional changes were small,
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Fig. 1 (See legend on next page.)
Jarman et al. Breast Cancer Research           (2019) 21:10 Page 5 of 18
HIF-1α expression peaked at 24 h in both cell lines
before dropping at later time points whilst HIF-2α ex-
pression was significantly increased by 48 h hypoxia
in both cell lines (P < 0.01). HIF-2α transcriptional
changes in response to hypoxia were very small when
compared to the large increase of HIF-2α seen when
HER2 is overexpressed; even after 72 h in hypoxia,
HIF-2α expression in MCF7 cells was at least 6-fold
lower than normoxic MCF7-HER2 samples. These
findings suggest that HIF-2α may be transcriptionally
regulated by HER2 signalling and that this can result
in an increase in HIF-2α protein even in the presence
of high oxygen concentrations. Interestingly, this pro-
vides novel evidence that HIF-1α and HIF-2α may be
differentially regulated by growth factor signalling and
that HER2 expression may be an important regulator
of HIF-2α, but not HIF-1α, in certain cellular
contexts.
HER2 overexpression in MCF7 increases the hypoxic
upregulation of HIF-2α and HIF target genes
Having established a role for HER2 expression and activ-
ity in driving HIF-2α transcription and protein levels in
normoxia, we next assessed the effect of HER2 on the
cellular response to hypoxia. For this, we used western
blotting to evaluate protein levels of HIF-1α, HIF-2α and
the well-characterised hypoxia response gene carbonic
anhydrase IX (CAIX) after incubation in hypoxic condi-
tions for 24, 48 and 72 h (Fig. 2a, b). In addition, we
used an Illumina BeadChip HT12v4 array (NCBI GEO
GSE111246) to assess global gene expression changes in
these cell lines in acute (24 h 0.5% O2) and chronic (10
weeks 0.5% O2) hypoxia, comparing the expression of a
number of known HIF-1 and HIF-2 target genes under
these conditions (Fig. 2c).
In accordance with canonical regulatory mechanisms,
hypoxia led to an increase in protein levels for both
HIF-1α and HIF-2α in both cell lines. Whilst HIF-1α
levels were comparable between cell lines, MCF7-HER2
had significantly higher HIF-2α levels across the hypoxic
time course when compared to wild-type MCF7 cells (P
= 0.028, two-way ANOVA). MCF7-HER2 have higher
levels of HIF-2α in normoxia (in agreement with Fig. 1),
and this increase in normoxic protein levels may be re-
sponsible for increased accumulation of HIF-2α in re-
sponse to hypoxia. CAIX expression was also more
highly upregulated in response to hypoxia in
MCF7-HER2 cells when compared to the wild-type
MCF7 cell line (p = 0.033). In addition to CAIX upregu-
lation at the protein level, analysis of microarray gene
expression data collected in normoxia (20% O2), acute
hypoxia (24 h 0.5% O2) and chronic hypoxia (10 weeks
0.5% O2) demonstrated an increased hypoxic upregula-
tion at the transcriptional level within the MCF7-HER2
cell line of HIF-1 genes (CAIX, ENO1, PFKFB3, PGK1)
[17, 18], HIF-2-specific genes (EFNA1, CITED2, IGFBP3,
HEY1) [36] and HIF-1/2-driven genes (GLUT1,
VEGF,HK2, BNIP3L) [17, 18, 37, 38] previously de-
scribed in the literature (Fig. 2c). In terms of
HIF-2-specific genes, CITED2, IGFBP3 and HEY1 have
been shown in a previous study [36] to require HIF-2α
for their hypoxic upregulation in MCF7 cells, supporting
the fact that these are HIF-2-mediated effects in this
model. The HER2-driven expression changes of these
genes in acute hypoxia are shown in Additional file 4:
Figure S4. Together, we have demonstrated that HER2
overexpression in this model is able to increase the hyp-
oxic upregulation of HIF-2α and functionally important
HIF-1 and HIF-2 target genes, potentially through in-
creased normoxic transcription of HIF-2α.
Hypoxic response genes are more highly expressed in
HER2-overexpressing 3D multicellular spheroids
Multicellular spheroids allow adherent cell lines nor-
mally grown in 2D to form 3D structures which more
closely resemble in vivo tumour structures (Fig. 3).
These spheroids naturally form a gradient of oxygen
concentration between their necrotic central region and
the well-perfused outer regions, making them a useful
model for studying the effects of hypoxia in tumours
and allowing these effects to be investigated with more
relevance to the tumour microenvironment and tumour
(See figure on previous page.)
Fig. 1 HER2 promotes HIF-2α expression in patient samples and a cell line model of HER2 overexpression. a HIF-2α is significantly higher in the
HER2-positive subtype when compared to Luminal A, Luminal B or Basal (P < 0.0001, one-way ANOVA). b Western blotting of MCF7 and MCF7-
HER2 cell lines shows increased HIF-2α levels in normoxia when HER2 is overexpressed. This was shown in untreated cells (U) and also cells
treated with 200 ng/ml NRG-1β for 1–6 h. NRG-1β treatment had no discernible effect on HIF-2α levels in either cell line. The bar graph shows
mean densitometry values of HIF-2α in untreated MCF7 and MCF7-HER2 whole cell lysates (n = 5 experiments, error bars represent SEM). HIF-2α
protein level was significantly higher in MCF7-HER2 when compared to wild-type MCF7 (P = 0.0041, unpaired t test). c Treatment of MCF7-HER2
with 10 μM lapatinib over 8, 24 and 48 h reduces normoxic HIF-2α expression. Mean densitometry values for HIF-2α relative to DMSO controls are
shown, with SEM represented by error bars and individual experimental repeats plotted. A representative western image of this result is also
shown (n = 4). d RT-PCR of HIF-1α and HIF-2α expression in MCF7 and MCF7-HER2 cell lines over 72 h hypoxia (0.5% oxygen). HIF-2α but not HIF-
1α expression is significantly higher in the HER2-overexpressing cell line when compared to wild-type MCF7 in normoxia (P < 0.0001). HIF-2α
expression was also significantly higher in MCF7-HER2 than in MCF7 cells after 8, 24, 48 and 72 h in hypoxia (0.5% oxygen) (P < 0.0001, one-way
ANOVA with Tukey’s multiple comparisons test (n = 3)). * = P < 0.05, ** = P < 0.01, *** = P < 0.005, **** = P < 0.0001
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histology than would be possible using monolayer cell
cultures.
Using multicellular spheroids of the MCF7 and
MCF7-HER2 cell lines, we were able to compare the ex-
pression of hypoxia response proteins across a 3D cellu-
lar structure through immunohistochemistry. Once
again, whilst the expression of HIF-1α was comparable
between cell lines, HIF-2α protein levels were signifi-
cantly higher in the context of HER2 overexpression (P
= 0.0002). Increased HIF-2α expression was not limited
to the hypoxic regions of the spheroids and was thus
consistent with a generalised increase in the HIF-2α pro-
tein driven by increased gene expression in normoxia.
Well-characterised hypoxia response genes CAIX,
LDHA and VEGF showed a similar effect, with signifi-
cantly increased expression across HER2-overexpressing
spheroids (P < 0.0001 in each case). CD44, a stem cell
marker and putative HIF target gene, was also signifi-
cantly increased in MCF7-HER2 spheroids (P < 0.0001),
but expression was predominantly limited to
peri-necrotic, hypoxic spheroid regions, suggesting an
interplay between HER2 and hypoxia in the expression
of this protein. This demonstrates that HER2-mediated
increases in HIF-2α and HIF target genes is also promin-
ent in a 3D model for tumour hypoxia, but suggests that
the upregulation of these hypoxic genes is promoted
across a range of oxygen concentrations in this model
when HER2 is overexpressed.
Microarray gene expression analysis demonstrates a
globally increased response to hypoxia in the context of
HER2 overexpression
Using our Illumina BeadChip experiment (NCBI GEO
GSE111246), we were able to examine transcriptomic
changes in response to acute (24 h) and chronic (10
weeks) hypoxia in MCF7 and MCF7-HER2 cell lines.
We used this global measurement of gene expression
changes to perform a more holistic assessment of how
HER2 overexpression affects cellular response to both
short-term and long-term hypoxia. Initially, the tran-
scriptional response to hypoxia was assessed through the
comparison of three previously described hypoxia gene
A B
C
Fig. 2 Increased upregulation of known hypoxia response genes in MCF7-HER2. Western blotting (a) and bar charts showing mean densitometry
values (error bars = SEM) (b) demonstrating the increased upregulation of HIF-2α (P = 0.028 (n = 4)) and CAIX (P = 0.033 (n = 5), two-way ANOVA)
in the MCF7-HER2 cell line after 24, 48 and 72 h hypoxia when compared to wild-type MCF7. No significant difference was observed for HIF-1α. c
Gene expression data from an Illumina BeadChip Array was used to compare the expression of known HIF target genes. Four genes reported to
be specific for each of HIF-1 and HIF-2 are shown alongside four genes targeted by both factors. For each gene, mean expression is shown for
MCF7 and MCF7-HER2 cell lines cultured in normoxia, acute (24 h) hypoxia or chronic (> 10 weeks) hypoxia (error bars = SEM). This demonstrates
the general trend toward and increased hypoxic regulation of these genes in the HER2-overexpressing cell line
Jarman et al. Breast Cancer Research           (2019) 21:10 Page 7 of 18
signatures [39–42] (Fig. 4a). These gene signatures have
been shown to act as prognostic indicators for various
cancer types including breast cancer, and together offer
a robust set of genes broadly associated with hypoxia.
Additionally, the upregulation of 448 HIF-1 and HIF-2
target genes previously determined through ChIP in
MCF7 cells [17, 18] was assessed after acute hypoxic ex-
posure in MCF7 and MCF7-HER2 cells (Fig. 4b). The
expression of these gene sets was compared through
hierarchical clustering of mean-centred log2 gene ex-
pression values in our cell lines (n = 3).
The majority of genes from the three published hyp-
oxia gene signatures [39–42] were found to be more
highly expressed in response to both acute and chronic
hypoxia than normoxia (red clusters, Fig. 4a). Interest-
ingly, the vast majority of these genes were increased to
a greater extent in the MCF7-HER2 cell line when com-
pared to wild-type MCF7. Despite no significant differ-
ences between cell lines in normoxia, expression of
these genes in acute hypoxia was significantly higher in
MCF7-HER2 compared to MCF7 for all three gene sig-
natures (Winter et al., P = 0.0241; Buffa et al., P = 0.0027;
Toustrup et al., P = 0.004), and gene expression in
chronic hypoxia was significantly higher in two out of
three signatures (Winter et al., P = 0.0032; Buffa et al., P
= 0.0266; one-way ANOVA with Tukey’s multiple com-
parisons test). This suggests that HER2 can promote a
stronger response to hypoxia across a broad set of hyp-
oxia response genes when overexpressed in this cell line.
Smaller gene clusters showed either reduced expression
in response to hypoxia (blue clusters, Fig. 4a), or no ex-
pression change in response to hypoxia (green clusters,
Fig. 4a). Interestingly, genes that were reduced in hyp-
oxia also had constitutively lower level expression in
MCF7-HER2 cells when compared to wild-type MCF7s.
This suggests that HER2 overexpression is able to
modulate both transcriptional up and downregulation of
genes in response to hypoxia. Finally, genes showing no
Fig. 3 HER2 increases the levels of HIF-2α and HIF target genes in 3D spheroids. Immunohistochemistry of MCF7 and MCF7-HER2 spheroids
shows the increased staining of HIF-2α, but not HIF-1α in MCF7-HER2. The increased levels of LDHA, CAIX, VEGF and CD44 were also shown.
Staining was scored out of 6 for intensity and staining area. Nuclear HIF-1α spheroids were scored as a percentage of stained nuclei. Scoring for
cytoplasmic or mixed staining of HIF-2α, LDHA, CAIX, CD44 and VEGF was done by first assigning a score of 0–6 for the area of staining coverage
(0 = 0–10% staining, 1 = 10–25%, 2 = 25–40%, 3 = 40–55%, 4 = 55–70%, 5 = 70–85% and 6 = 85–100%) and a score of 0–3 for staining intensity,
with 0 representing no visible staining, 1 being faint staining and 3 being intense staining (this was scored independently of the area covered). A
final score was established by dividing the area score by 2 and adding it to the intensity score. Scoring was performed using only the viable
regions of the spheroids and excluding necrotic central areas which were clearly distinguished by a loss of cellularity. Mean scoring (error bars =
SEM) is shown for a minimum of seven spheroids from a representative experiment with n = 3 repeats. T tests were performed, and P values for
the differences between cell lines are shown. (Scale bars = 250 μm (inset image scale bars = 50 μm)
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change in hypoxia (green cluster) were still constitutively
higher in MCF7-HER2 despite no response to hyp-
oxia, suggesting that the transcriptional regulation of
hypoxic response genes which are not
hypoxia-inducible in this model (due either to sub-
optimal conditions for activation or not being part of
the cell-type-specific hypoxia transcriptional
programme) may still be promoted by the increased
expression of the HER2 receptor. Using the online
bioinformatics tool DAVID, we assessed the enrich-
ment of gene ontology terms relating to biological
processes in these clusters and found that genes more
strongly upregulated by hypoxia in MCF7-HER2 (red
clusters) showed a significant increase (P < 0.0001) in
GO (gene ontology) terms pertaining to hypoxic re-
sponse and glycolysis in all three gene signatures.
Genes involved included a large number of known
glycolytic genes (ALDOA, PDK1, PFKFB3, PFKP,
ENO1, PGK1, GPI, HK2 and PGAM1) as well as a
number of non-glycolytic drivers of cancer progres-
sion (CAIX, VEGFA, LOX and ANGPTL4).
We performed hierarchical clustering analysis on a set
of HIF-1 and HIF-2 target genes previously identified
through ChIP in MCF7 cells (Fig. 4b) [17, 18]. These
genes demonstrated similar clustering to the hypoxic
signatures (Fig. 4a), with a large number of genes show-
ing increased upregulation by acute hypoxia in the
HER2-overexpressing cell line when compared to
wild-type MCF7 cells (red clusters). Additionally, a large
number of HIF target genes were expressed to a higher
degree in normoxia in MCF7-HER2 (green clusters).
The differences seen in these cell lines demonstrate an
enhanced transcriptional response to hypoxia driven by
HER2 overexpression. This was seen both for general
hypoxia gene signatures as well as for genes shown to be
HIF-1 or HIF-2 targets in MCF7 cells. These
HER2-mediated transcriptional changes appear to in-
clude sets of genes whose expression in hypoxia is mod-
ulated by HER2 as well as a number of hypoxia or HIF
target genes which are constitutively increased by HER2
in the presence of high oxygen concentrations. The
modulation of hypoxic response genes by HER2
A B
Fig. 4 HER2 overexpression promotes the transcriptional upregulation of hypoxia metagenes and HIF target genes in hypoxia. a Three hypoxic gene
signatures (top: Winter et al. (2007), middle: Buffa et al. (2010), bottom: Toustrup et al. (2011)) reported to show genes commonly altered by hypoxia
were assessed in microarray gene expression data of MCF7 and MCF7-HER2 cultured in normoxia, acute hypoxia or chronic hypoxia. In general, MCF7-
HER2 showed a stronger induction of a large proportion of genes upregulated in acute and chronic hypoxia (red clusters), with no equivalent seen for
MCF7 cells. In addition, the larger signatures contained clusters which appeared to be downregulated by hypoxia in MCF7. These were constitutively
lower in MCF7-HER2 (blue clusters), suggesting an increased hypoxic response in terms of both upregulated and downregulated genes. Finally, a small
cluster in the largest signature (green) showed no hypoxic response, but these genes were still constitutively higher in MCF7-HER2. b Hierarchical
clustering of HIF target genes (as determined from combined gene lists of two references Mole et al. 2009 and Schӧdel et al. 2011 who used ChIP in
MCF7 to identify HIF-1 and HIF-2 target genes) was used to assess the hypoxic upregulation of HIF target genes in MCF7 and MCF7-HER2 in acute
hypoxia. A large proportion of HIF targets were either constitutively higher in MCF7-HER2 (green), more strongly induced in hypoxia in MCF7-HER2
(red), or downregulated in hypoxia whilst being constitutively low in MCF7-HER2 (blue). Beside this, a small proportion behaved similarly between cell
lines (pink) or were more strongly induced in MCF7 (black)
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overexpression may therefore have important conse-
quences for tumour progression both in the context of
tumour hypoxia as well as in well-perfused tumour
regions.
HER2 overexpression in MCF7 enhances the cellular
hypoxic response through primed and HER2-specific gene
upregulation
We assessed global transcriptional changes in MCF7 and
MCF7-HER2 cells in response to acute and chronic hyp-
oxia. This allowed significant gene expression changes to
be identified without the use of predefined gene sets.
Hypoxia-upregulated genes in each cell line were deter-
mined through rank product testing (FDR < 0.05) for
both acute and chronic hypoxia. These gene lists were
then compared to genes significantly upregulated in
MCF7-HER2 in normoxia compared to wild-type MCF7.
The genes belonging to each group are shown in a Venn
diagram, with the proportion of HIF target genes in each
group also shown (Fig. 5a). This analysis further demon-
strates an important role for HER2 in modifying the
transcriptional response to hypoxia. Notably, the
number of hypoxia responsive genes which were consti-
tutively highly expressed in MCF7-HER2 in normoxia
was far greater than those constitutively higher in
MCF7. Out of the genes which were constitutively highly
expressed in normoxia in the context of HER2 overex-
pression, 14.4% were also upregulated in response to
acute hypoxia and 18.6% by chronic hypoxia. This com-
pares to just 1.2% and 7.6% for acute and chronic hyp-
oxia respectively when genes more highly expressed in
wild-type MCF7 are considered. This suggests HER2
drives the normoxic expression of genes which are up-
regulated in hypoxia and this is in concordance with
hierarchical clustering of hypoxia gene signatures in
these cell lines (Fig. 4). When genes with no significant
difference in normoxic expression between cell lines are
considered, we see an enrichment for HIF target genes
that are upregulated by hypoxia in MCF7-HER2 but not
in MCF7. HIF target genes make up just 1.6% (acute)
and 5.6% (chronic) of genes induced by hypoxia specific-
ally in MCF7 cells, compared to 19% (acute) and 14.1%
(chronic) of genes induced in MCF7-HER2 cells. These
findings support the gene expression changes seen
A B
Fig. 5 HER2 expression primes cells for hypoxia in MCF7-HER2 cells. Rank product testing of gene expression data (FDR = 0.05) was used to identify
genes which were significantly induced in hypoxia (performed separately for acute and chronic) in each cell line and compared to genes significantly
more highly expressed in either of the cell lines (A). The number of genes belonging into each category is shown in the centre of each pie chart, with
the proportion of those genes represented by HIF-1, HIF-2 or HIF-1/HIF-2 target genes shown in green red or blue, respectively. Notably, a larger
proportion of HIF target genes are present in hypoxic response unique to MCF7-HER2 when compared to the unique MCF7 response in acute and
chronic hypoxia. Additionally, a relatively large proportion of genes which can be induced by hypoxia are constitutively increased by in MCF7-HER2,
with little or no equivalent set constitutively upregulated in MCF7. This suggests that HER2 overexpression can prepare the cells for hypoxia with the
normoxic expression of both HIF-regulated and non-HIF hypoxia response genes. Hypoxia response genes constitutively upregulated in MCF7-HER2
(primed genes) and genes involved in the hypoxic response in MCF7-HER2 only (HER2-specific genes) contain a number of pathologically interesting
genes involved in a number of important cellular processes (B)
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through hierarchical clustering of hypoxia metagenes
and HIF target genes (Fig. 4) which demonstrate a role
for HER2 in driving both an exacerbated response to
hypoxia as well as a normoxic increase of
hypoxia-associated genes.
To more fully understand the consequences of the
HER2-mediated hypoxic response, genes shown to be
upregulated by hypoxia specifically in HER2-positive
cells (‘HER2-specific’) and hypoxia-responsive genes
shown to be more highly expressed in MCF7-HER2 than
in wild-type MCF7 in normoxia (‘HER2-primed’) were
assessed for known roles in breast cancer (Fig. 5b).
Genes involved in glycolysis, invasion/metastasis, angio-
genesis, tumour microenvironment regulation and pro-
liferation were identified in acute hypoxia, with an
additional upregulation of DNA repair/maintenance and
treatment resistance genes shown in chronic hypoxia.
Interestingly, a large number of genes associated with
notch signalling were also found in acute and chronic
hypoxia, suggesting this may promote an epithelial to
mesenchymal transition phenotype in these cells under
hypoxia [43–48].
To determine the relevance of this effect to other cell
lines, the expression of these primed hypoxic response
genes was compared to HER2 expression across a
meta-analysis of gene expression data for 173 breast cancer
cell line samples from 3 previously integrated studies [33]
(Fig. 6a). This established a set of acute (n = 25) and chronic
(n = 33) hypoxic response genes whose expression corre-
lated significantly (P < 0.05) with HER2 expression across
cell lines, supporting a widespread role for the
HER2-driven exacerbated hypoxic response as represented
by our isogenic cell line model. Figure 6b shows the top 5
acute and chronic hypoxic response genes correlating to
HER2 expression: EIG121, P4HA1, S100P, NUPR1 and
SOX4. Autophagy regulator EIG121 is known to promote
cell survival under stress [49] and has been shown to in-
crease metastatic capacity in breast cancer cell lines [50].
P4HA1 is a component of the prolyl-4-hydroxylase in-
volved in collagen synthesis and ECM remodelling [51].
S100P is a calcium-binding protein with a number of cellu-
lar functions which has been directly associated with me-
tastasis and poor survival in breast cancer [52]. NUPR1 is a
stress response protein frequently amplified in breast can-
cer; whilst it has a large set of varied roles in the cell, its ex-
pression has been associated with progression and
chemoresistance in breast cancer [53]. Finally, SOX4 is a
known driver of EMT and metastatic potential in breast
cancer [54, 55]. This demonstrates a strong interrelation-
ship between HER2 expression in breast cancer cell lines
and the expression of hypoxia response genes which drive
metastasis and breast cancer progression, suggesting a rela-
tionship between HER2 and a response to hypoxia which is
detrimental in terms of disease progression.
HER2-overexpressing breast cancer cell lines display
increased sensitivity to HIF-2 inhibition
Having established a role for HER2 overexpression in
driving an exacerbated hypoxic response and the in-
creased expression of HIF-2α, we investigated whether
HER2-positive cell lines were more sensitive to specific
inhibition of HIF-2α. The growth of MCF7 and
MCF-HER2 cell lines was compared in response to
HIF-2α-specific knock-down by siRNA. Western blotting
was used to confirm the HIF-2α-specific effect of two
siRNA treatments; a single siRNA targeting HIF-2α
(siRNA #4) and a pool of four individual HIF-2α target-
ing siRNAs (SMARTpool siRNA). Both treatments re-
duced HIF-2α to less than 10% of the level seen in
untreated cells, mock transfected cells or cells treated
with non-targeting siRNA; no discernible effect on
HIF-1α was seen (Fig. 7a). In addition, these siRNAs
were also able to reduce the levels of HIF-2α induced by
hypoxia to levels below the detectable limit in
MCF7-HER2 cells (Fig. 7b). Transfection of MCF7 and
MCF7-HER2 cell lines with these siRNAs in sulforhoda-
mine B (SRB) growth assays performed in normoxia or
hypoxia over 5 days demonstrated an increased sensitiv-
ity in the HER2-overexpressing cell line to HIF-2α
knock-down (Fig. 7c). MCF7-HER2 cells showed reduced
cell density after treatment with either HIF-2α-specific
siRNA in normoxia or hypoxia, whilst MCF7 cells were
generally unaffected showing reduced cell density with
just one of the siRNAs only in normoxia. MCF7-HER2
were significantly more sensitive to siRNA treatment than
MCF7 cells in all treatment categories, indicating an in-
creased dependence on HIF-2α in HER2-overexpressing
cells in normoxia and hypoxia.
To verify the sensitivity of HER2-overexpressing breast
cancer cell lines to HIF-2α-specific inhibition, we tested the
effect of HIF-2α-specific translation inhibitor C76 [56] on
the growth rates of eight breast cancer cell lines, including
three ER-positive/HER2-negative lines (MCF7, T47D,
ZR751), three naturally HER2-positive cell lines (BT474,
MDA-MB-361, SKBR3) and two triple negative cell lines
(HBL100, MDA-MB-231) (Fig. 7d). IC50 values for this
compound were determined in each cell line under nor-
moxic cell culture conditions (Fig. 7e). Non-normalised
growth curves for individual cell lines are shown in Add-
itional file 5: Figure S5. This analysis showed that all three
of the HER2-positive cell lines had an increased sensitivity
to HIF-2α inhibition through C76 treatment with between
1.8- and 7-fold increase in sensitivity when compared to
other cell lines. IC50 values for HER2-positive cell lines
ranged from 1.83 to 5.68 μM, with ER-positive/HER2-nega-
tive lines ranging from 10.40 to 12.16 μM and triple nega-
tive cell lines from 12.16 to 12.82 μM. This provides further
evidence that HIF-2-specific inhibitors may be more effect-
ive in HER2-overexpressing breast cancers.
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High HIF-2α and HIF-2 target gene expression are
indicators of poor outcome in HER2-positive breast
cancer patients
To understand the impact of HIF-2α expression on
breast cancer patient survival, we used gene
expression and clinical survival data from the publicly
available METABRIC [34] breast cancer dataset to as-
sess whether HIF-2α and HIF target genes are associ-
ated with outcome. Breast cancer samples were
separated into HER2-positive (n = 236) and
A
B
Fig. 6 HER2 expression primes cells for hypoxia across breast cancer cell lines. a Genes which were primed for either acute or chronic hypoxia by HER2
overexpression in MCF7 were compared to HER2 expression in a data set containing gene expression data from 173 samples representing 77 different breast
cancer cell lines. Genes with significant (P<0.005) correlation to HER2 expression in this data set are shown (acute n=25, chronic n=33 with 16 genes
represented in both acute and chronic hypoxia). The expression of these genes is shown in a heatmap with cell lines ordered by HER2 expression. b Five
example genes with roles in cancer pathology which are primed by HER2 for both acute and chronic hypoxia and correlate to HER2 in breast cancer cell lines.
Bar charts (error bars = SEM, n=3) of the expression of these genes in MCF7 and MCF7-HER2 is shown to demonstrate their increased hypoxic upregulation in
HER2-overexpressing cells. P values and Pearson’s correlation to HER2 expression in the cell lines data set are shown
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HER2-negative (n = 1662) based on IHC-determined
HER2 status. We used the survivALL R package (pre-
viously described by Pearce et al. [35]) to perform ex-
haustive survival analysis and obtain P values using
Cox-proportional hazards model for every possible
cut-point based on HIF-2α expression level. This dem-
onstrated that high HIF-2α expression is associated
with disease-specific survival in HER2-positive tu-
mours (P = 0.0197, HR = 6.81, at the most significant
cut-point). A total of 56 out of 235 cut-points (23.8%)
were significant (P < 0.05) (grey bar in Fig. 8a), demon-
strating that significant differences in survival between
these groups are robust. Interestingly, HIF-2α was
only associated with worse prognosis in the
HER2-positive group, and not when HER2-nega-
tive, or the unstratified patient cohort is consid-
ered (Additional file 6: Figure S6). Equivalent
analysis of HIF-2α and nine genes shown to be
specifically driven by HIF-2 in MCF7 [36] demon-
strated that when stratified by the average expres-
sion of these genes, patients with high mean
expression show significantly worse disease-specific
survival (P = 0.0176, HR = 5.13) (Fig. 8b, c). To-
gether, this survival analysis demonstrates a robust
relationship between HIF2α expression (or the ex-
pression of HIF2α-driven genes) and poor






Fig. 7 HER2-overexpressing cell lines are more sensitive to HIF-2α inhibition. a Western blot showing siRNAs knock-down of HIF-2α in MCF7-HER2 in
normoxia. SiRNa knock-down was performed with 25 μM of four different siRNAs as well as 5–100 μM of SMARTpool, combined siRNAs. Protein level
was reduced to < 10% of that in cells treated with an equivalent concentration of non-targeting siRNA up to 96 h after treatment. SiRNAs #4 and
SMARTpool (10 μM) were chosen for the following experiments as HIF-2α was convincingly reduced and HIF-1α levels were not affected (data not
shown). b Pre-treatment with either siRNA but not controls was effective at stopping the hypoxic upregulation of HIF-2α in MCF7-HER2 cells. This
resulted in undetectable levels of HIF-2α protein after 24, 48 and 72 h hypoxia (0.5% oxygen). c MCF7 and MCF7-HER2 cells were treated with HIF-2α
siRNAs and grown on 96-well plates for 5 days in either normoxia or hypoxia. Cellular density was assessed by SRB assay. Bars represent OD values
relative to the non-targeting control (error bars = SEM, n = 12 repeats from n = 2 individual experiments). Differences between targeting and non-
targeting siRNAs were assessed in each cell line using ANOVA with Dunnett’s multiple comparison test. In normoxia and hypoxia, MCF7-HER2 cellular
growth was significantly reduced by both siRNA when compared to non-targeting siRNA (P < 0.0001 in all cases). MCF7 growth was reduced
significantly by just one of the siRNAs in normoxia (P < 0.0001), and this was to a lesser extent than MCF7-HER2. In hypoxia, MCF7 was unaffected by
either siRNA. MCF7-HER2 growth was inhibited to a significantly greater degree when compared to wild-type MCF7 for both siRNAs in normoxia (P =
0.0421 and P = 0.0004) and hypoxia (P < 0.0001 in both cases). d Breast cancer cell lines, including ER+/HER2- (MCF7/T47D/ZR751), HER2+ (MDAMB361,
SKBR3, BT474) and triple-negative (MDAMB231 and HBL100) cells were treated for 5 days with C76 a specific inhibitor of HIF-2α translation. A range of
concentrations were tested and an IC50 value for each cell line was established (e). All HER2+ cell lines had lower IC50 values for this compound, with
no difference between ER+/HER2− and triple-negative lines
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Discussion
HIF-1α expression in breast cancer is associated with
more aggressive disease as HIF target genes can promote
cancer cell survival in the hypoxic tumour microenvir-
onment by regulating processes such as glycolysis,
angiogenesis and metastasis [14, 57, 58]. It is now known
that as well as the canonical regulatory mechanism
which allows the accumulation of HIF-1α protein when
molecular oxygen is limited, HIF-1α protein levels can
be increased by growth factor signalling even in the
presence of oxygen [24, 25]. Despite this, we still do not
understand how growth factor signalling modulates the
A
B C
Fig. 8 HIF-2α expression and activity is associated with worse disease-specific survival in HER2-positive breast cancer. a Kaplan-Meier plot
showing disease-specific survival in the publically available Metabric dataset. Patients were divided into HIF-2α high and low categories using the
optimum cut-off, with additional significant (P < 0.05) cut-offs shown represented by the grey bar. In HER2-positive breast cancers (n = 236) high
HIF-2α expression was associated with significantly worse disease-specific survival (P = 0.0197, HR = 6.81). b, c A set of 9 HIF-2-specific genes
reported in the literature were taken along with HIF-2α to see if their mean expression was also associated with worse survival in HER2-positive
patients. Samples were ordered by their mean expression of the 10 genes and an optimum cut-off point for survival analysis was determined (c)
(all significant cut-offs shown in grey). A high mean expression of these genes was associated with disease-specific survival in HER2-positive
breast cancer (b)
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cellular response to hypoxia, or what implications this
has for HER2-positive breast cancer. In this paper, we
use an isogenic breast cancer cell line model for HER2
overexpression to assess the effect of increased HER2
signalling on the transcriptional response to acute (24 h)
and chronic (> 10 weeks) hypoxia.
This study provides evidence for important interplay be-
tween HER2 and HIF-2α in breast cancer pathology. We
have shown that HER2 overexpression is sufficient to in-
crease cellular levels of HIF-2α but not HIF-1α in nor-
moxia, demonstrating a novel role for the lesser studied
protein. In contrast to previously described mechanisms
of growth factor-regulated HIF-1α, which involves pertur-
bations to post-translational regulation and protein stabil-
ity [24, 25], this HER2-driven increase in HIF-2α was
found to occur at the level of transcription and coincided
with increased gene expression levels of the HIF2A gene
seen in the HER2-positive subtype in a large meta-analysis
of breast tumours. We have also shown that the increased
expression of HER2 in these cells promotes the upregula-
tion of HIF-2α protein in response to hypoxia, with no
discernible effect on HIF-1α. HIF-2α upregulation was
inhibited by treatment with lapatinib (Fig. 1c) and PI3K
inhibitor LY294002 (Additional file 3: Figure S3C). Whilst
the exact mechanisms governing the differential normoxic
upregulation of HIF-1α and HIF-2α are still unclear, this
suggests that signalling through AKT may play a role in
both. HER2 overexpression also led to the increased ex-
pression of previously reported HIF-1 and HIF-2-specific
target genes, and an increase in protein levels of hypoxia
response genes in a 3D model which recapitulates the oxy-
gen gradient seen in the tumour microenvironment. This
included proteins previously described as HIF-1-specific
targets, such as carbonic anhydrase IX (CAIX) [59] and
lactate dehydrogenase A (LDHA) [14, 60]. Together, this
not only provides novel evidence that the non-canonical
regulation of HIF-α subunits extends to HIF-2α, but sug-
gests that an increase in HIF-2α levels through such
mechanisms is sufficient in driving the hypoxic expression
of various hypoxic response genes.
We propose that the potential for the different HIF-α
family members to drive the transcription of unique tar-
get genes may be plastic and context-specific and that
the regulation of HIF-1α and HIF-2α levels by growth
factor signalling may be an important mechanism by
which the expression of numerous hypoxia response
genes is modified. Previous efforts to define the differ-
ences between the transcriptional targets of HIF-1 and
HIF-2 in breast cancer have focussed on using the
MCF7 cell line as a model [17, 18, 36], but further work
may be required to define HIF targets and the differ-
ences in HIF target selection in various breast cancer
types in order to understand when targeting HIF activity
may be an effective therapeutic strategy.
We have shown a generalised increase in the expres-
sion of hypoxia response genes under acute and chronic
hypoxia when HER2 is overexpressed. This included the
increased upregulation of previously characterised hyp-
oxic response gene signatures, which have been shown
to have prognostic potential in multiple cancer types in-
cluding breast cancer [39–42]. The HER2-mediated in-
crease in the expression of these genes in hypoxia
suggests that the increased aggressiveness of
HER2-positive breast cancer may in part be due to the
increased potential for these cells to respond to hypoxic
stress. Furthermore, by comparing global gene expres-
sion changes in response to hypoxia, we have shown that
HER2 overexpression in MCF7 promotes the constitu-
tive normoxic expression of genes also induced by hyp-
oxia. In this way, we demonstrate the ability of HER2
expression to not only exacerbate the cellular response
to hypoxia, but to promote a primed state, whereby nu-
merous pathologically relevant hypoxia response genes
(including identified HIF-1 and HIF-2 target genes) are
driven in normoxia. We also found a number of these
‘primed’ hypoxic response genes to be correlated with
HER2 expression across breast cancer cell lines, suggest-
ing that the HER2-mediated upregulation of these genes
is not unique to our isogenic cell line model. This ana-
lysis included a number of genes known to be involved
in cell motility, invasion and metastasis, suggesting that
the increase in HIF2A expression by HER2 may drive
these characteristics in patients with HER2-positive
breast cancers and may explain the relationship between
HIF2A expression and survival in these patients.
Finally, we investigated the potential for HIF-2α-targeted
therapy in HER2-positive breast cancer. Whilst HIF-1α ex-
pression has been consistently associated with disease pro-
gression and worse prognosis in breast cancer [10, 20, 61–
63], the prognostic implications of HIF-2α expression have
remained unclear [64, 65]. Here, we show that when survival
analysis of the METABRIC patient cohort is performed in
HER2-positive breast cancer patients only, HIF-2α expres-
sion and activity is clearly associated with worse
disease-specific survival. We also demonstrated an increased
sensitivity of HER2-positive breast cancer cell lines to
HIF-2α-specific inhibition, using siRNA and the previously
described HIF-2α translation inhibitor C76 [56]. This sug-
gests that in HER2-positive breast cancers targeting HIF-2α
activity may be an effective therapeutic intervention and war-
rants further investigation. The efficacy of HIF-targeted ther-
apy is currently being investigated in a number of cancer
types, and thus a number of compounds which target HIF
activity either directly or indirectly have been developed [66,
67]. This has included an increased recognition of the im-
portant differences between HIF-1 and HIF-2 inhibition and
the development of HIF-2-specific inhibitors [56, 68]. How-
ever, the application of these compounds in breast cancer
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therapy to date is highly limited and the majority of these
therapeutic approaches have focussed entirely on HIF-1 in-
hibition, with the efficacy of HIF-2 inhibition being largely
limited to renal cell carcinoma [69–72].
Conclusions
In this study, we have shown that HER2 overexpression
in MCF7 cells leads to an increase in HIF-2α levels in
normoxia and the increased upregulation of HIF-2α in
response to hypoxia; this demonstrates novel mechanis-
tic differences in the growth factor-mediated regulation
of HIF-1α and HIF-2α in breast cancer cells. In addition,
we have shown that HER2 overexpression in this model
drives the expression of a large number of hypoxic re-
sponse genes both in normoxia and in response to acute
(24 h) and chronic (10 weeks) hypoxia, suggesting that
growth factor signalling may exacerbate the cellular re-
sponse to hypoxia through HIF-2α. We have not only
demonstrated a direct relationship between HER2 over-
expression and HIF-2α in breast cancer cell lines and pa-
tient gene expression data, but have shown both an
increased sensitivity of HER2-positive cell lines to
HIF-2-specific inhibition and demonstrated the ability of
HIF-2α- or HIF-2-specific target genes to act as prog-
nostic indicators for disease-specific survival in
HER2-positive breast cancers. This shows that HER2 ex-
pression may be an important determinant in the role of
HIF-2 in breast cancer pathology and that the effective-
ness of HIF-targeted therapies for breast cancer may de-
pend on the expression of growth factor receptors such
as HER2. Further investigation into the mechanisms
governing the HER2-mediated regulation of HIF tran-
scription factors is needed to fully understand the con-
tribution of HIF-driven transcription to cancer
progression in normoxia and hypoxia and may lead to
new insights into how specific and non-specific
HIF-targeted therapeutics can be more effectively ap-
plied clinically to the treatment of breast cancer.
Additional file
Additional file 1: Figure S1. HIF-1α and HIF-2α expression across the
molecular subtypes of breast cancer. HIF1A (A) and HIF2A (B) gene ex-
pression in a combined meta-analysis of 2999 breast cancer patient pa-
tients stratified by molecular subtype. Boxes represent the median, upper
and lower quartiles, whilst range is represented by the whiskers. The
number of patients attributed to each category is shown below the mo-
lecular subtype. ANOVA with Tukey’s multiple comparisons shows signifi-
cantly higher expression of HIF1A in more aggressive subtypes whilst
HIF2A is more highly expressed in the HER2-positive subtype only. Ad-
justed P values are shown on the right hand side. (PDF 153 kb)
Additional file 2: Figure S2. HIF2A expression is higher in cell lines
with high HER2 expression. A cell line data set containing 173 samples
representing 77 different breast cancer cell lines was used to compare
HIF2A with HER2 expression. A) Box plot showing the expression of
HIF2A in HER2-low (n = 121) and HER2-high (n = 52) cell line samples.
HER2-high cell lines have significantly higher levels of HIF2A expression
(P = 0.03, Wilcoxon signed-rank test). B) Cell lines ordered by HER2 expres-
sion to show the cut-off used to determine HER2-high and HER2-low
groups. (PDF 181 kb)
Additional file 3: Figure S3. Regulation of HIF-2α by AKT and ERK sig-
nalling pathways. A) MCF7 and MCF7-HER2 cells show similar increases in
nuclear HIF-1α after treatment with 200 ng/ml NRG-1β. HIF-1α protein
levels were compared by western blotting of nuclear and cytoplasmic ly-
sates collected from cells treated with NRG-1β for 1–6 h after 20 h in 0%
FCS phenol red-free media. Β-actin is included as a loading control. B)
Western blotting experiments show the increase in AKT(S473) and ERK1/
2(T202/Y204) phosphorylation in response to treatment with 200 ng/ml
NRG-1β in MCF7 and MCF7-HER2 cells. Levels of phosphorylated AKT and
ERK1/2 are comparable between cell lines both in untreated cells and
after NRG-1β treatment (representative from n = 4 experimental repeats.
C) MCF7-HER2 cells were treated with PI3K inhibitor LY294002 (10 μM) or
dual specificity MEK kinase inhibitor PD98059 (50 μM) for 8 h before
whole lysate collection. Blotting for phosphorylated ERK1/2 (T202/Y204)
and AKT (S473) demonstrate the specific inhibition of these pathways by
their respective inhibitors. D) OD measurements of HIF-2α protein levels
in LY294002 and PD98059 treated lysates compared to equivalent vehicle
(DMSO) controls in western blotting experiments shown in C. HIF-2α
levels were significantly reduced after PI3K inhibition (ratio pair t-test, P <
0.05).Whilst inhibition of ERK phosphorylation led to a reduction in HIF-2α
levels in all experimental repeats, this did not achieve significance (repre-
sentative of n = 4 experimental repeats). (PDF 157 kb)
Additional file 4: Figure S4. HER2-driven hypoxic expression of HIF-2α-
specific target genes. The expression levels of IGFBP3, CITED2 and HEY1
in MCF7 and MCF7-HER2 in normoxia and after exposure to acute (24 h)
hypoxia in our Illumina Beadchip microarray data. Individual expression
values for n = 3 repeats is shown with mean values represented by blue
(MCF7) or red (MCF7-HER2) lines. These target genes have been previ-
ously demonstrated by siRNA inhibition of HIF-1α and HIF-2α to be spe-
cifically upregulated by HIF-2α in MCF7 cells [28]. The upregulation of
gene expression in response to acute hypoxia is greatly facilitated by the
overexpression of HER2. (ANOVA with Tukey’s multiple comparisons, ***
= P < 0.001). (PDF 13 kb)
Additional file 5: Figure S5. Cell growth assays show increased
sensitivity of HER2-positive cell lines to HIF-2α inhibition. Sulforhodamine
B growth assays for cell lines treated with a range of concentrations of
HIF-2 translation inhibitor C76 or vehicle control (DMSO). The data shown
is the non-normalised version of the growth curves shown in Fig. 7D.
Briefly, cells were treated with 10 nM–100 μM of C76 or equivalent vol-
umes of DMSO for 5 days, at which point cellular density was assessed by
SRB assay. Error bars represent the SEM from n = 6 repeats. (PDF 51 kb)
Additional file 6: Figure S6. HIF2a is associated with worse prognosis
only in HER2-positive breast cancer. Kaplain-Meier plots showing disease-
specific survival in the METABRIC dataset in all patients (A), HER2-positive
patients (B) and HER2-negative patients (C). HIF-2α high and low categor-
ies were determined by the optimum cut-off point, whilst the complete
data set used median HIF-2α expression, as no suitable significant cut-offs
were present. All significant cut-off points are illustrated by grey bars
above the plots, with the number of patients in each category shown as
blue and red bars. HER2 positivity was determined by IHC or FISH in asso-
ciated clinical metadata. HIF-2α was only significantly associated with
worse prognosis in HER2-positive patients. (PDF 290 kb)
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